Diffuse Scleroderma clinical trials at UCSF

2 research studies open to eligible people

Showing trials for

  • BMS-986278 in Participants With Progressive Pulmonary Fibrosis

    open to eligible people ages 21 years and up

    The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

    San Francisco 5391959, California 5332921 and other locations

  • Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

    open to eligible people ages 18-65

    The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.

    San Francisco 5391959, California 5332921 and other locations

Last updated: